Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen.
from The Medical News http://ift.tt/1DvcxvX
from The Medical News http://ift.tt/1DvcxvX
No comments:
Post a Comment